🍄 Mushroom power in medicine is growing, but proof is needed

Mushrooms are gaining traction in medicine due to their bioactive compounds with anticancer and anti-inflammatory effects. Researchers are focusing on over 1.5 million identified species, with nearly 200 being edible for human consumption. Studies show extracts from mushrooms like Coriolus versicolor improved survival in gastric cancer patients after gastrectomy. Furthermore, adding Grifola frondosa extract boosted recovery and survival for advanced laryngeal cancer patients. More standardized, large-scale clinical trials are necessary to fully prove these therapeutic potentials. 🍄

😔 Understanding Premenstrual Dysphoric Disorder (PMDD)

Giulia experienced severe mood swings, irritability, and bloating before her period, leading to a provisional diagnosis of PMDD. This condition affects about 2-5% of menstruating women and is often mistaken for PMS or other disorders. PMDD is diagnosed when prominent affective symptoms cause significant distress during the luteal phase. Differentiation from conditions like PME and bipolar disorder is crucial for accurate care. Doctors require prospective daily recording over two cycles to confirm the PMDD pattern. 😔

🤯 Mahakali glimpse rocks with Akshay Khanna's transformation

The first glimpse of Mahakali, a mythological saga, has dropped, showing a grand expansion of the PVCU. Bollywood powerhouse Akshay Khanna is unveiled as Shukracharya in this film, marking his debut in Telugu cinema. The glimpse was released recently, setting the stage for a massive visual spectacle. The story explores identity and the clash of Dharma versus Adharma, fueled by past injustices. Audiences are now eagerly awaiting the full trailer to see more of this epic narrative.

🎬 Drishyam 3 ends franchise, aims for career best opening

The crime mystery thriller, Drishyam 3, is set to conclude the iconic franchise with its third installment. It stars Ajay Devgn and is scheduled for release on October 2nd. The previous part in 2022 earned 241 crore net in India, setting high expectations. This conclusion aims for Ajay Devgn's biggest opening ever at the Indian box office. The film is expected to surpass Singham Again's current record of 43.7 crore net. 🎬

🌟 Suriya's film hits 100 crore net again

Vishwanath And Sons has officially crossed the 100 crore net mark at the Indian box office. The film, starring Suriya and Mamitha Baiju, earned 7.3 crore on its tenth day. Overall, the movie has collected 100.65 crore net, which is Suriya's second such film after Karuppu. This marks the third centurion film of 2026 for Kollywood. The film is projected to run for two more weeks despite the release of Toxic on August 26. 🎬

💰 Dhamaal franchise crosses 100 crore net profit mark

Indra Kumar's slapstick comedy franchise, Dhamaal, has officially surpassed a major box office milestone. The franchise, starring Ajay Devgn and others, is seen across four installments released over time. As of Day 45 for Dhamaal 4, the cumulative net profit across all films reached 102.71 crore. This success comes after Dhamaal 4 added 0.05 lakh on its 45th day, pushing its India Net Collection to 177.91 crore. The four films collectively earned over 575 crore gross collection worldwide.

🌟 Jana Nayagan close to dethroning Karuppu

Jana Nayagan is nearing the opportunity to surpass Karuppu's lifetime collection in India. The film stars Thalapathy Vijay and was released in theaters on July 23 in India. As of its fifth Sunday, the movie collected 0.26 crore net in India, with a total net collection of 197.91 crore. This puts Jana Nayagan just 0.28 crore away from beating Karuppu's domestic box office target. The film, which had a budget of 350 crore, is expected to conclude with a loss in India. 💰

🕷️ Spider-Man: Brand New Day nears Endgame record

Tom Holland's Spider-Man: Brand New Day is aggressively climbing the North American box office charts. The film is currently set to surpass Avengers: Endgame as Marvel's highest-grossing entry domestically. As of its fourth Sunday, the film had earned $12.2 million, bringing its domestic total to $854.9 million. It only needs $3.47 million more to beat Endgame's $858,373,000 domestic haul by the end of Monday. This milestone could also put it in contention to challenge Star Wars: The Force Awakens' record. 🎬

🔥 Yash's Toxic hits big box office advance sales

Yash's film Toxic is showing massive hype with its advance bookings. The movie is currently the 8th biggest Hindi opener of 2026, seen across national multiplex chains. As of August 24, the film has earned a net advance collection of 10.79 crore. This figure surpasses Alia Bhatt’s Alpha and Shahid Kapoor’s O Romeo. With only 40 hours left, Toxic could challenge Dhamaal 4's opening figures. 🚀

🧬 New drug targets tough blood cancers via MYC and GSPT1

Researchers at MD Anderson Cancer Center discovered a new feedforward relationship between MYC and GSPT1 in various blood cancers. The experimental drug GT19630 was developed to disrupt this cycle in leukaemia, lymphoma, and multiple myeloma. Preclinical tests on January 2024 showed strong anti-cancer activity, even against TP53-mutated disease. This mechanism also showed promise in overcoming resistance to venetoclax in AML. Further studies are needed to confirm the safety and efficacy of this approach in patients.

🔬 Drug keeps HIV viral suppression high in French study

Dolutegravir-Lamivudine showed high viral suppression rates in a 3-year French real-world study. Researchers monitored 304 participants across 49 centers in France from 2020 to 2024. Nearly 90% of treatment-naive individuals suppressed the virus within 6 months, while 94% of pretreated patients maintained suppression. This indicates strong virological success with a favorable safety profile, showing stable body weight. Future studies need to look at longer-term results in different populations. 🔬